Mesoblast Ltd (ASX:MSB,NASDAQ:MESO) has been granted a trading halt by the ASX this morning, pending details of a fully underwritten capital raising.
The raising will comprise an accelerated non-renounceable entitlement offer.
The company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates.
The halt will remain in place until the opening of trade on Tuesday 29th August 2017, or earlier if an announcement is made to the market.